|
|
|
News For ELN;BIIB From The Last 14 Days Check below for free stories on ELN;BIIB the last two weeks. |
|
|
| May 16, 2013 | | 07:29 EDT |  | BIIB | Leerink to host a bus tour
Boston Biopharma Bus Tour travels throughout Boston on May 16-17. | | | May 15, 2013 | | 17:21 EDT |  | ELN | Elan publishes response document regarding Echo Pharma offer
Elan announces publication of a response document in respect of the Echo Pharma Acquisition Limited offer made on May 2. The response document is published in accordance with Rules 25 and 30.3 of the Irish Takeover Rules and the United States tender offer rules. As previously advised, the Board of Elan has unanimously, and without reservation, rejected the offer by Royalty Pharma. Shareholders are strongly advised to take no action in relation to the offer. | | | May 14, 2013 | | 15:09 EDT | | BIIB | Biogen has a conference call hosted by JPMorgan
JPMorgan Analysts Meacham and Kasimov host a conference call with CEO George Scangos and CFO Paul Clancy on May 17 at 10 am. | | | 07:07 EDT |  | ELN | Theravance price target raised to $54 from $44 at Stifel
Stifel thinks that Theravance's (THRX) royalty deal with Elan (ELN) demonstrates its ability to generate revenue that had not been reflected in its stock price. The firm expects Theravance to make similar deals in the future and it keeps a Buy rating on the stock. | | | May 13, 2013 | | 16:25 EDT |  | ELN | On The Fly: Closing Wrap
Stocks on Wall Street were little changed from their opening levels as investors weighed the potential end of the Fed's quantitative easing program against a better than expected report on retail sales. The Wall Street Journal's Jon Hilsenrath suggested in a report over the weekend that the Federal Reserve has mapped a QE exit strategy. The report paired with the retail sales data left the market lacking conviction in either direction today, as the averages spent the majority of the session range-bound near the flatline. ECONOMIC EVENTS: In the U.S., retail sales rose 0.1% in April, which beat expectations for a 0.3% decline. Retail sales excluding autos, gas, and building materials rose 0.6%, which was also better than expected. Business inventories were flat in March, versus expectations for a 0.3% gain. In Asia, Chinese factory output grew 9.3% annually in April, which was up from 8.9% in March but still missed expectations for a 9.5% growth rate. COMPANY NEWS: The Supreme Court ruled unanimously that Monsanto's (MON) patented genetically altered soybeans are protected and that farmers cannot use them to create new seeds without paying the company... Dell's (DELL) special committee publicly asked for more information from Carl Icahn and Southeastern Asset Management about their proposed leveraged recapitalization. This request follows television interviews by Icahn last Friday in which he discussed his Dell proposal, as well as a weekend report in Barron's saying the Icahn and Southeastern plan could be a better deal for shareholders. MAJOR MOVERS: Among the notable gainers was Theravance (THRX), up $6.26, or 17.92%, to $41.20 after Elan Corporation (ELN) bought a stake in the potential future royalty payments from four respiratory programs partnered with GlaxoSmithKline (GSK) in exchange for $1B in cash. Also higher was Tesla (TSLA), which rose $11.04, or 14.38%, to $87.80 in its third straight double-digit percentage gain following a better-than-expected earnings report last week. Among the noteworthy losers was Barnes & Noble (BKS), down $2.21, or 9.48%, to $21.10 after the blog InsiderMonkey disputed a previous report about Microsoft's (MSFT) interest in the bookseller's NOOK assets. Also lower was JoS. A. Bank (JOSB), down $3.31, or 7.16%, to $42.90 after the company's first quarter earnings view came in below expectations. INDICES: The Dow was down 26.81, or 0.18%, to 15,091.68; the Nasdaq was up 2.21, or 0.06%, to 3,438.79; and the S&P 500 was nearly unchanged at 1,633.77. | | | 12:20 EDT | | ELN | On The Fly: Midday Wrap
 Subscribe for More Information | | | 11:12 EDT | | BIIB | Biogen MS drug scripts grew 38% week-over-week, says Leerink
Subscribe for More Information | | | 09:25 EDT | | ELN | On The Fly: Pre-market Movers
Subscribe for More Information | | | 07:34 EDT | | BIIB | Biogen says FDA accepts BLA for Eloctate
Subscribe for More Information | | | 05:44 EDT | | ELN | Elan provides additional information on Elan/Theravance agreement
Subscribe for More Information | | | | 05:35 EDT | | ELN | Theravance, Elan enter into $1B royalty participation agreement
Subscribe for More Information | | | 05:31 EDT | | ELN | Theravance, Elan enter into $1B royalty participation agreement
| | | 05:26 EDT | | ELN | Theravance to host conference call
Subscribe for More Information | | | May 10, 2013 | | 08:00 EDT | | BIIB | Biogen should be bought on weakness before Q2 Tecfidera data, says Stifel
Stifel recommends buying Biogen on any weakness before the company reports Q2 Tecfidera sales data. The firm thinks that any continued strength in Tecfidera prescription data will cause analysts to revise their estimates higher, and it keeps a Buy rating on the shares. | | | May 9, 2013 | | 16:59 EDT | | BIIB | Isis Pharmaceuticals earns $3.5M from Biogen
Subscribe for More Information | | | May 6, 2013 | | 08:09 EDT | | BIIB | Biogen MS drug on track to top consensus by $400M, says Deutsche Bank
Deutsche Bank says IMS scripts indicate Biogen's multiple sclerosis treatment Tecfidera is on track to top consensus expectations by $400M in 2013. The firm says that if scripts stabilize at current levels, Tecfidera U.S. sales would come in at $651M for 2013, above the consensus of $248M. Deutsche has a Buy rating on shares of Biogen with a $240 price target. | |
|
|
|
|
|
|
